Label-Free Enrichment of Circulating Tumor Plasma Cells: Future Potential Applications of Dielectrophoresis in Multiple Myeloma.
Nicolò MussoAlessandra RomanoPaolo Giuseppe BonacciGrazia ScanduraClarissa PandinoMassimo CamardaGiorgio Ivan RussoFrancesco Di RaimondoEmma CacciolaRossella CacciolaPublished in: International journal of molecular sciences (2022)
In multiple myeloma (MM), circulating tumor plasma cells (CTPCs) are an emerging prognostic factor, offering a promising and minimally invasive means for longitudinal patient monitoring. Recent advances highlight the complex biology of plasma cell trafficking, highlighting the phenotypic and genetic signatures of intra- and extra-medullary MM onset, making CTPC enumeration and characterization a new frontier of precision medicine for MM patients, requiring novel technological platforms for their standardized and harmonized detection. Dielectrophoresis (DEP) is an emerging label-free cell manipulation technique to separate cancer cells from healthy cells in peripheral blood samples, based on phenotype and membrane capacitance that could be successfully tested to enumerate and isolate CTPCs. Herein, we summarize preclinical data on DEP development for CTPC detection, as well as their clinical and research potential.
Keyphrases
- label free
- induced apoptosis
- circulating tumor
- prognostic factors
- multiple myeloma
- cell cycle arrest
- minimally invasive
- peripheral blood
- circulating tumor cells
- cell therapy
- newly diagnosed
- signaling pathway
- genome wide
- single cell
- end stage renal disease
- cell death
- oxidative stress
- gene expression
- cell free
- stem cells
- loop mediated isothermal amplification
- mesenchymal stem cells
- risk assessment
- cross sectional
- climate change
- big data
- quantum dots